The report puts the 7MM soft tissue sarcoma market at USD 310 million in 2025, with the United States accounting for about 85% and pipeline drugs expected to broaden treatment options.
DelveInsight said the soft tissue sarcoma, or STS, market is set to expand at a 7.9% CAGR during 2022–2036, supported by rising diagnosis, improving disease recognition, advances in precision medicine, and a pipeline of emerging therapies. The firm said the STS market in the 7MM — the United States, EU4, the United Kingdom, and Japan — was worth USD 310 million in 2025, with the United States accounting for about 85% of the total. It estimated about 40,000 new STS cases across the 7MM in 2025, including more than 13,500 in the United States, and said incidence is expected to rise gradually through 2036. Companies named in the report include Takara Bio, Intensity Therapeutics, PharmaMar, Jazz Pharmaceuticals, Polaris, Advenchen Laboratories, Philogen, Sun Pharma, Eli Lilly, Replimune, Immutep, US WorldMeds, GSK, and QBiotics Group. Pipeline therapies cited include TBI-1301 (mipetresgene autoleucel), INT230-6, ZEPZELCA (lurbinectedin), Pegargiminase, Catequentinib Hydrochloride (AL3818), Fibromun, Abemaciclib (VERZENIO), Vusolimogene Oderparepvec (RP1) + Nivolumab, Pembrolizumab (KEYTRUDA) + Eftilagimod Alpha, Letetresgene autoleucel, Risvutatug rezetecan, and Tigilanol Tiglate. DelveInsight said the current treatment landscape spans localized, advanced, metastatic, and recurrent disease, with chemotherapy, targeted therapies, and tyrosine kinase inhibitors still forming the backbone of care while cell therapies, immune checkpoint inhibitors, and biomarker-guided approaches expand the field. Approved agents such as Crizotinib (XALKORI) and Trabectedin (YONDELIS) remain important for certain subtypes, while engineered T-cell therapies including TBI-1301 target NY-ESO-1-expressing tumors. The release highlighted recent developments including Philogen's planned Phase III Fibromun study, completion of enrollment in PharmaMar's Phase III SaLuDo trial of ZEPZELCA plus doxorubicin, orphan-drug designation for eftilagimod alfa, and a temporary enrollment pause in Intensity Therapeutics' INVINCIBLE-3 trial due to funding constraints. DelveInsight also said lurbinectedin is anticipated to enter the U.S. market in 2028 and is expected to generate notable revenue at launch.